James MD - SpringWorks Therapeutics Chief Officer
| SWTX Stock | USD 41.73 0.51 1.24% |
Insider
James MD is Chief Officer of SpringWorks Therapeutics
| Age | 64 |
| Address | 100 Washington Boulevard, Stamford, CT, United States, 06902 |
| Phone | 203 883 9490 |
| Web | https://www.springworkstx.com |
SpringWorks Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3428) % which means that it has lost $0.3428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5933) %, meaning that it created substantial loss on money invested by shareholders. SpringWorks Therapeutics' management efficiency ratios could be used to measure how well SpringWorks Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, SpringWorks Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 13.3 M in 2024, whereas Other Assets are likely to drop slightly above 2.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Fischbach | Revolution Medicines | 43 | |
| Desiree DDS | Passage Bio | N/A | |
| Mark Murcko | Relay Therapeutics | 64 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Michael MacLean | Avidity Biosciences | 58 | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Andy Porter | Relay Therapeutics | N/A | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 52 | |
| Nello MD | Kymera Therapeutics | 45 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| MBA MD | Pliant Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 |
SpringWorks Therapeutics Leadership Team
Elected by the shareholders, the SpringWorks Therapeutics' board of directors comprises two types of representatives: SpringWorks Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SpringWorks. The board's role is to monitor SpringWorks Therapeutics' management team and ensure that shareholders' interests are well served. SpringWorks Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SpringWorks Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Badreddin Edris, Chief Officer | ||
| Mary Smith, Chief Officer | ||
| Kim Diamond, Vice Relations | ||
| James MD, Chief Officer | ||
| Michael Nofi, Chief Officer | ||
| TaiAn Lin, Chief Officer | ||
| Saqib JD, CEO Director | ||
| MBA Perier, Chief Officer | ||
| Bhavesh MBA, Chief Officer | ||
| Bhavesh Ashar, Chief Officer | ||
| Herschel JD, General Secretary | ||
| Daniel Pichl, Chief Officer |
SpringWorks Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SpringWorks Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (2.03) % | ||||
| Operating Margin | (1.18) % | ||||
| Current Valuation | 2.7 B | ||||
| Shares Outstanding | 74.39 M | ||||
| Shares Owned By Insiders | 2.01 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 12.29 M | ||||
| Price To Earning | 6.14 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.